Skip navigation

DSpace

機構典藏 DSpace 系統致力於保存各式數位資料(如:文字、圖片、PDF)並使其易於取用。

點此認識 DSpace
DSpace logo
English
中文
  • 瀏覽論文
    • 校院系所
    • 出版年
    • 作者
    • 標題
    • 關鍵字
    • 指導教授
  • 搜尋 TDR
  • 授權 Q&A
    • 我的頁面
    • 接受 E-mail 通知
    • 編輯個人資料
  1. NTU Theses and Dissertations Repository
  2. 公共衛生學院
  3. 流行病學與預防醫學研究所
請用此 Handle URI 來引用此文件: http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17484
完整後設資料紀錄
DC 欄位值語言
dc.contributor.advisor簡國龍(Kuo-Liong Chien)
dc.contributor.authorHsiao-Ting Juangen
dc.contributor.author莊筱婷zh_TW
dc.date.accessioned2021-06-08T00:15:46Z-
dc.date.copyright2013-09-24
dc.date.issued2013
dc.date.submitted2013-07-30
dc.identifier.citation1. Mukherjee D, Patil CG. Epidemiology and the global burden of stroke. World Neurosurg 2011;76:S85-90.
2. Organization WH. The Global Burden of Disease: 2004 Update. In; 2004.
3. The summary of cause of death statistics in 2011. Department of Health, Executive Yuan, R.O.C. (Taiwan). (Accessed November 20, 2012, at http://www.doh.gov.tw/CHT2006/DM/DM2_2.aspx?now_fod_list_no=12336&class_no=440&level_no=4.)
4. Chien KL, Sung FC, Hsu HC, Su TC, Lin RS, Lee YT. Apolipoprotein A-I and B and stroke events in a community-based cohort in Taiwan: report of the Chin-Shan Community Cardiovascular Study. Stroke 2002;33:39-44.
5. Mohan KM, Wolfe CD, Rudd AG, Heuschmann PU, Kolominsky-Rabas PL, Grieve AP. Risk and cumulative risk of stroke recurrence: a systematic review and meta-analysis. Stroke 2011;42:1489-94.
6. Tseng MC, Lin HJ. Readmission after hospitalization for stroke in Taiwan: results from a national sample. Journal of the Neurological Sciences 2009;284:52-5.
7. Samsa GP, Bian J, Lipscomb J, Matchar DB. Epidemiology of recurrent cerebral infarction: a medicare claims-based comparison of first and recurrent strokes on 2-year survival and cost. Stroke 1999;30:338-49.
8. Furie KL, Kasner SE, Adams RJ, Albers GW, Bush RL, Fagan SC, Halperin JL, Johnston SC, Katzan I, Kernan WN, Mitchell PH, Ovbiagele B, Palesch YY, Sacco RL, Schwamm LH, Wassertheil-Smoller S, Turan TN, Wentworth D. Guidelines for the prevention of stroke in patients with stroke or transient ischemic attack: a guideline for healthcare professionals from the american heart association/american stroke association. Stroke 2011;42:227-76.
9. Sacco RL, Benjamin EJ, Broderick JP, Dyken M, Easton JD, Feinberg WM, Goldstein LB, Gorelick PB, Howard G, Kittner SJ, Manolio TA, Whisnant JP, Wolf PA. American Heart Association Prevention Conference. IV. Prevention and Rehabilitation of Stroke. Risk factors. Stroke 1997;28:1507-17.
10. Xu G, Liu X, Wu W, Zhang R, Yin Q. Recurrence after ischemic stroke in chinese patients: impact of uncontrolled modifiable risk factors. Cerebrovascular Diseases 2007;23:117-20.
11. Kleijer BC, van Marum RJ, Egberts AC, Jansen PA, Knol W, Heerdink ER. Risk of cerebrovascular events in elderly users of antipsychotics. Journal of Psychopharmacology 2009;23:909-14.
12. Chang CH, Shau WY, Kuo CW, Chen ST, Lai MS. Increased risk of stroke associated with nonsteroidal anti-inflammatory drugs: a nationwide case-crossover study. Stroke 2010;41:1884-90.
13. Wu CS, Wang SC, Cheng YC, Gau SS. Association of cerebrovascular events with antidepressant use: a case-crossover study. American Journal of Psychiatry 2011;168:511-21.
14. Pan A, Sun Q, Okereke OI, Rexrode KM, Hu FB. Depression and risk of stroke morbidity and mortality: a meta-analysis and systematic review. JAMA 2011;306:1241-9.
15. Wu CS, Shau WY, Chan HY, Lee YC, Lai YJ, Lai MS. Utilization of antidepressants in Taiwan: a nationwide population-based survey from 2000 to 2009. Pharmacoepidemiology and Drug Safety 2012.
16. ATC/DDD Index. 2013. (Accessed 12.12, 2012, at http://www.whocc.no/atc_ddd_index/.)
17. Goodman & Gilman's Pharmacological Basis of Therapeutics. 12th ed. Chapter 15. Drug Therapy of Depression and Anxiety Disorders. The New York: McGraw-Hill, 2011. (Accessed at http://www.accessmedicine.com/content.aspx?aID=16663059.)
18. Hackett ML, Yapa C, Parag V, Anderson CS. Frequency of depression after stroke: a systematic review of observational studies. Stroke 2005;36:1330-40.
19. El Husseini N, Goldstein LB, Peterson ED, Zhao X, Pan W, Olson DM, Zimmer LO, Williams JW, Jr., Bushnell C, Laskowitz DT. Depression and antidepressant use after stroke and transient ischemic attack. Stroke 2012;43:1609-16.
20. Williams LS, Ghose SS, Swindle RW. Depression and other mental health diagnoses increase mortality risk after ischemic stroke. American Journal of Psychiatry 2004;161:1090-5.
21. Yuan HW, Wang CX, Zhang N, Bai Y, Shi YZ, Zhou Y, Wang YL, Zhang T, Zhou J, Yu X, Sun XY, Liu ZR, Zhao XQ, Wang YJ. Poststroke depression and risk of recurrent stroke at 1 year in a Chinese cohort study. PLoS ONE 2012;7:e46906.
22. Sathyanarayana Rao TS, Andrade C. Exploring new frontiers in neuropsychopharmacology: SSRIs for stroke. Indian J Psychiatry 2011;53:283-6.
23. Santarelli L, Saxe M, Gross C, Surget A, Battaglia F, Dulawa S, Weisstaub N, Lee J, Duman R, Arancio O, Belzung C, Hen R. Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants. Science 2003;301:805-9.
24. Mikami K, Jorge RE, Adams HP, Davis PH, Leira EC, Jang MJ, Robinson RG. Effect of Antidepressants on the Course of Disability Following Stroke. American Journal of Geriatric Psychiatry 2011;19:1007-15.
25. Chollet F, Tardy J, Albucher JF, Thalamas C, Berard E, Lamy C, Bejot Y, Deltour S, Jaillard A, Niclot P, Guillon B, Moulin T, Marque P, Pariente J, Arnaud C, Loubinoux I. Fluoxetine for motor recovery after acute ischaemic stroke (FLAME): a randomised placebo-controlled trial. Lancet Neurol 2011;10:123-30.
26. Hackett ML, Anderson CS, House AO, Xia J. Interventions for Treating Depression After Stroke. Stroke 2009.
27. Mead GE, Hsieh CF, Lee R, Kutlubaev MA, Claxton A, Hankey GJ, Hackett ML. Selective serotonin reuptake inhibitors (SSRIs) for stroke recovery. Cochrane Database Syst Rev 2012;11:CD009286.
28. Schlienger RG, Meier CR. Effect of selective serotonin reuptake inhibitors on platelet activation: can they prevent acute myocardial infarction? Am J Cardiovasc Drugs 2003;3:149-62.
29. Maurer-Spurej E, Pittendreigh C, Solomons K. The influence of selective serotonin reuptake inhibitors on human platelet serotonin. Thrombosis and Haemostasis 2004;91:119-28.
30. Muhonen MG, Robertson SC, Gerdes JS, Loftus CM. Effects of serotonin on cerebral circulation after middle cerebral artery occlusion. Journal of Neurosurgery 1997;87:301-6.
31. Razzaque Z, Heald MA, Pickard JD, Maskell L, Beer MS, Hill RG, Longmore J. Vasoconstriction in human isolated middle meningeal arteries: determining the contribution of 5-HT1B- and 5-HT1F-receptor activation. British Journal of Clinical Pharmacology 1999;47:75-82.
32. Mortensen JK, Larsson H, Johnsen SP, Andersen G. Post stroke use of selective serotonin reuptake inhibitors and clinical outcome among patients with ischemic stroke: a nationwide propensity score-matched follow-up study. Stroke 2013;44:420-6.
33. Kharofa J, Sekar P, Haverbusch M, Moomaw C, Flaherty M, Kissela B, Broderick J, Woo D. Selective serotonin reuptake inhibitors and risk of hemorrhagic stroke. Stroke 2007;38:3049-51.
34. de Abajo FJ, Jick H, Derby L, Jick S, Schmitz S. Intracranial haemorrhage and use of selective serotonin reuptake inhibitors. British Journal of Clinical Pharmacology 2000;50:43-7.
35. Bak S, Tsiropoulos I, Kjaersgaard JO, Andersen M, Mellerup E, Hallas J, Garcia Rodriguez LA, Christensen K, Gaist D. Selective serotonin reuptake inhibitors and the risk of stroke: a population-based case-control study. Stroke 2002;33:1465-73.
36. Douglas I, Smeeth L, Irvine D. The use of antidepressants and the risk of haemorrhagic stroke: a nested case control study. British Journal of Clinical Pharmacology 2011;71:116-20.
37. Chen Y, Guo JJ, Li H, Wulsin L, Patel NC. Risk of cerebrovascular events associated with antidepressant use in patients with depression: a population-based, nested case-control study. Annals of Pharmacotherapy 2008;42:177-84.
38. Trifiro G, Dieleman J, Sen EF, Gambassi G, Sturkenboom MC. Risk of ischemic stroke associated with antidepressant drug use in elderly persons. Journal of Clinical Psychopharmacology 2010;30:252-8.
39. Smoller JW, Allison M, Cochrane BB, Curb JD, Perlis RH, Robinson JG, Rosal MC, Wenger NK, Wassertheil-Smoller S. Antidepressant Use and Risk of Incident Cardiovascular Morbidity and Mortality Among Postmenopausal Women in the Women's Health Initiative Study. Archives of Internal Medicine 2009;169:2128-39.
40. Coupland C, Dhiman P, Morriss R, Arthur A, Barton G, Hippisley-Cox J. Antidepressant use and risk of adverse outcomes in older people: population based cohort study. BMJ 2011;343:d4551.
41. Pequignot R, Tzourio C, Peres K, Ancellin ML, Perier MC, Ducimetiere P, Empana JP. Depressive symptoms, antidepressants and disability and future coronary heart disease and stroke events in older adults: the Three City Study. European Journal of Epidemiology 2013;28:249-56.
42. Levesque LE, Hanley JA, Kezouh A, Suissa S. Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 2010;340:b5087.
43. Liu J, Weinhandl ED, Gilbertson DT, Collins AJ, St Peter WL. Issues regarding 'immortal time' in the analysis of the treatment effects in observational studies. Kidney International 2012;81:341-50.
44. 全民健康保險研究資料庫. 2013. (Accessed 03.12, 2013, at http://nhird.nhri.org.tw/date_cohort.htm.)
45. 健保用藥品項查詢. 2011 (Accessed 12.12, 2012, at http://www.nhi.gov.tw/query/query1.aspx?menu=21&menu_id=713&webdata_id=3510&WD_ID=851.)
46. Simon R, Makuch RW. A non-parametric graphical representation of the relationship between survival and the occurrence of an event: application to responder versus non-responder bias. Statistics in Medicine 1984;3:35-44.
47. Schultz LR, Peterson EL, Breslau N. Graphing survival curve estimates for time-dependent covariates. Int J Methods Psychiatr Res 2002;11:68-74.
48. Andersen PK, Gill RD. Cox's regression model for counting processes: a large sample study. The annals of statistics 1982;10:1100-20.
49. Fisher LD, Lin DY. Time-dependent covariates in the Cox proportional-hazards regression model. Annual Review of Public Health 1999;20:145-57.
50. Hackam DG, Mrkobrada M. Selective serotonin reuptake inhibitors and brain hemorrhage: a meta-analysis. Neurology 2012;79:1862-5.
51. de Abajo FJ, Gil MJ, Bryant V, Timoner J, Oliva B, Garcia-Rodriguez LA. Upper gastrointestinal bleeding associated with NSAIDs, other drugs and interactions: a nested case-control study in a new general practice database. European Journal of Clinical Pharmacology 2013;69:691-701.
52. Moride Y, Abenhaim L. Evidence of the depletion of susceptibles effect in non-experimental pharmacoepidemiologic research. Journal of Clinical Epidemiology 1994;47:731-7.
53. Caughey GE, Preiss AK, Vitry AI, Gilbert AL, Ryan P, Shakib S, Esterman A, McDermott RA, Roughead EE. Does antidepressant medication use affect persistence with diabetes medicines? Pharmacoepidemiology and Drug Safety 2013.
54. Ho PM, Rumsfeld JS, Masoudi FA, McClure DL, Plomondon ME, Steiner JF, Magid DJ. Effect of medication nonadherence on hospitalization and mortality among patients with diabetes mellitus. Archives of Internal Medicine 2006;166:1836-41.
55. Cheng CL, Kao YH, Lin SJ, Lee CH, Lai ML. Validation of the National Health Insurance Research Database with ischemic stroke cases in Taiwan. Pharmacoepidemiology and Drug Safety 2011;20:236-42.
56. Castro VM, Gallagher PJ, Clements CC, Murphy SN, Gainer VS, Fava M, Weilburg JB, Churchill SE, Kohane IS, Iosifescu DV, Smoller JW, Perlis RH. Incident user cohort study of risk for gastrointestinal bleed and stroke in individuals with major depressive disorder treated with antidepressants. BMJ Open 2012;2:e000544.
dc.identifier.urihttp://tdr.lib.ntu.edu.tw/jspui/handle/123456789/17484-
dc.description.abstract背景:過去研究服用抗憂鬱藥物與中風復發之相關性的結果還尚未清楚。本篇研究將評估中風病患服用抗憂鬱藥物是否會增加中風復發之風險。
方法:本篇的世代研究追蹤了在2000年到2009年台灣健康保險資料庫中18884名年齡20歲以上的中風(包含出血性與缺血性中風)初發患者。在追蹤期間每一個病人的抗憂鬱藥物處方之紀錄被取得,並且抗憂鬱藥物之種類以解剖學治療學及化學分類系統的定義分類:三環類的抗憂鬱藥物(tricyclic antidepressants, TCAs)、選擇性血清素再吸收抑制劑(selective serotonin reuptake inhibitors, SSRIs)、單胺氧化酶抑制劑(monoamine oxidase inhibitors, MAOIs)及其他。研究所追蹤的結果為在追蹤期間發生中風復發。研究分析使用時間相依的Cox 比例風險迴歸模型。
結果:在61892人年的追蹤期間,有4450個中風復發事件發生。在調整其他變項後,服用抗憂鬱藥物會增加中風復發風險(風險比值(hazard ratio [HR]), 1.41; 95%信賴區間(95% confidence interval [CI]), 1.24-1.61),尤其是缺血性中風(HR, 1.47; 95% CI, 1.28-1.68),而出血性中風則無(HR, 1.23; 95% CI, 0.89-1.71)。使用抗憂鬱藥物種類中的TCAs (HR, 1.52; 95% CI, 1.24-1.87)、其他分類(HR, 1.42; 95% CI, 1.12-1.80)、或是多重種類一起(HR, 1.87; 95% CI, 1.06-3.30)使用時會使中風復發風險增加。
結論:使用抗憂鬱藥物會增加中風復發之風險,特別是缺血性中風,未來需要有更多研究來了解其中的生理機轉。
zh_TW
dc.description.abstractBackground - The evidence about the association between use of antidepressants and stroke recurrence was scanty. This study evaluated the risk of stroke recurrence of using antidepressants in patients with stroke from a national representative cohort.
Methods – This cohort study followed 18884 patients aged 20 years who had an incident stroke from 2000 to 2009 from National Health Insurance Research Database in Taiwan. Records of each antidepressant prescription were obtained during follow-up. The types of antidepressants were categorized by Anatomical Therapeutic Chemical classification system: tricyclic antidepressants (TCAs), selective serotonin reuptake inhibitors (SSRIs), monoamine oxidase inhibitors (MAOIs), and other antidepressants. The main outcome was a recurrent stroke during the follow-up period. A time-dependent Cox proportional hazards model was used in the analyses.
Results – During 61892 person-years of follow-up, we documented 4450 events for stroke recurrence. Antidepressants use was associated with an increased risk of stroke recurrence (adjusted hazard ratio [HR], 1.41; 95% confidence interval [CI], 1.24-1.61]), especially in ischemic stroke (HR, 1.47; 95% CI, 1.28-1.68), but not in hemorrhagic stroke (HR, 1.23; 95% CI, 0.89-1.71). The increased risk for stoke recurrence was found in TCAs (HR, 1.52; 95% CI, 1.24-1.87), the group of other types (HR, 1.42; 95% CI, 1.12-1.80), or multiple types (HR, 1.87; 95% CI, 1.06-3.30).
Conclusions – We demonstrated that use of antidepressants was associated with an increased risk of stroke recurrence, especially in ischemic stroke among Taiwanese. Further studies are warranted to confirm the possible underlying mechanisms of these findings.
en
dc.description.provenanceMade available in DSpace on 2021-06-08T00:15:46Z (GMT). No. of bitstreams: 1
ntu-102-R00849018-1.pdf: 1305479 bytes, checksum: 754d39e59ef40556be141a41a8805e04 (MD5)
Previous issue date: 2013
en
dc.description.tableofcontents口試委員會審定書 I
誌謝 II
中文摘要 III
Abstract IV
目錄 VI
表目錄 VIII
圖目錄 X
第一章 背景 1
第一節 中風的復發及其危險因子 1
第二節 抗憂鬱藥物的使用及定義 1
第三節 中風後使用抗憂鬱藥物 3
第四節 抗憂鬱藥物與中風之相關性文獻回顧及研究問題 4
第五節 小結 7
第二章 研究目的及假說 8
第一節 研究目的 8
第二節 研究假設 8
第三章 研究方法 9
第一節 研究設計及資料來源 9
第二節 研究樣本 10
第三節 主要研究變項 11
第四節 主要研究觀察發生之事件終點 12
第五節 其他研究之共變項 12
第六節 統計分析 13
第一項 描述性統計 13
第二項 模式分析 14
第三項 統計工具及檢力之估計 15
第四章 研究結果 16
第一節 描述性結果 16
第二節 主要結果 17
第三節 次要結果分析 18
第四節 分層分析及敏感度分析 18
第五章 討論 20
第一節 研究主要發現 20
第二節 研究其他發現 21
第三節 研究優勢與限制 22
第四節 未來應用及發展 23
第五節 結論 23
參考資料 24
附件 52
dc.language.isozh-TW
dc.title使用抗憂鬱藥物對中風復發之相關性研究zh_TW
dc.titleUsing Antidepressants and the Risk of Stroke Recurrenceen
dc.typeThesis
dc.date.schoolyear101-2
dc.description.degree碩士
dc.contributor.coadvisor陳培君(Pei-Chun Chen)
dc.contributor.oralexamcommittee張淑惠(Shu-Hui Chang),高淑芬(Shur-Fen Gau),季瑋珠(Wei Chu Chie)
dc.subject.keyword中風,抗憂鬱藥物,藥物流行病學,時間相依模型,台灣健康保險資料庫,zh_TW
dc.subject.keywordstroke,antidepressants,pharmacoepidemiology,time-dependent model,National Health Insurance Research Database in Taiwan,en
dc.relation.page52
dc.rights.note未授權
dc.date.accepted2013-07-30
dc.contributor.author-college公共衛生學院zh_TW
dc.contributor.author-dept流行病學與預防醫學研究所zh_TW
顯示於系所單位:流行病學與預防醫學研究所

文件中的檔案:
檔案 大小格式 
ntu-102-1.pdf
  未授權公開取用
1.27 MBAdobe PDF
顯示文件簡單紀錄


系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。

社群連結
聯絡資訊
10617臺北市大安區羅斯福路四段1號
No.1 Sec.4, Roosevelt Rd., Taipei, Taiwan, R.O.C. 106
Tel: (02)33662353
Email: ntuetds@ntu.edu.tw
意見箱
相關連結
館藏目錄
國內圖書館整合查詢 MetaCat
臺大學術典藏 NTU Scholars
臺大圖書館數位典藏館
本站聲明
© NTU Library All Rights Reserved